![Lorem Title](/uploads/t1_ef07277633.png?width=3840&quality=100)
Lorem Title
The Biopharmaceutical facility established by Turgut Pharmaceuticals in Gebze, which developed and produced Turkey's first end-to-end Biosimilar Monoclonal Antibody and completed its Phase 1 study, received the TITCK Approved GMP Certificate.